Browse All
Displaying 6 - 7 of 7
Author:Vermersch, Patrick Krieger, Stephen Wiendl, Heinz Granziera, Cristina Mao-Draayer, Yang Cutter, Gary Kalbus, Oleksandr Staikov, Ivan Dufek, Michal Montalban, Xavier Saubadu, Stephane Luo, Xiaodong Smyth, Brendan Djukic, Biljana Truffinet, Philippe Wallstroem, Erik Giovannoni, Gavin
Session Name:P7: Multiple Sclerosis: Clinical Trials 1
Topic:Multiple Sclerosis
Program Number:P7.003
Author Institution:University of Lille, Inserm U1172 LilNCog, CHU Lille, FHU Precise, Lille, France, Lille, France Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Icahn School of Medicine at Mount Sinai, New York, NY, United States, New York, NY Department of Neurology and Neurophysiology, University of Freiburg, Freiburg, Germany Brain & Mind Institute, University of Sydney, Sydney, Australia, Freiburg im Breisgau, Germany Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, Faculty of Medicine Neurologic Clinic and Policlinic, MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, Basel, Switzerland, Basel, Switzerland Autoimmunity Center of Excellence, Oklahoma Medical Research Foundation, Oklahoma City, OK, United States, Oklahoma City, OK Department of Biostatistics, UAB School of Public Health, Birmingham, AL, United States, Birmingham, AL Department of Neurology, Dnipro State Medical University, Dnipro, Ukraine, Dnipro, Ukraine Clinic of Neurology and Sleep Medicine, Acibadem City Clinic University Hospital Tokuda, Sofia, Bulgaria, Sofia, Bulgaria First Department of Neurology, St. Anne’s University Hospital, Faculty of Medicine, Masaryk University, Brno, Czech Republic, Brno, Czech Republic Multiple Sclerosis Centre of Catalonia, Department of Neurology, Vall d'Hebron University Hospital, Barcelona, Spain , Barcelona, Spain Sanofi, Gentilly, France, Chilly Mazarin, France Sanofi, Morristown, NJ, United States, Morristown, NJ Sanofi, Cambridge, MA, United States, Cambridge, MA Queen Mary University of London, London, United Kingdom, London, United Kingdom
Author:Fox, Robert J. Bar-Or, Amit Traboulsee, Anthony Oreja-Guevara, Celia Giovannoni, Gavin Vermersch, Patrick Syed, Sana Li, Ye Vargas, Wendy S. Turner, Timothy J. Wallstroem, Erik Reich, Daniel S.
Program Number:P7.004
Author Institution:Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, United States, OH Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, University of Pennsylvania, Philadelphia, United States, PA The University of British Columbia, Division of Neurology, Vancouver, Canada, BC, Canada Departamento de Neurologia, Hospital Clinico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain, Spain Queen Mary University London, Blizard Institute, Barts and The London School of Medicine and Dentistry, London, United Kingdom, United Kingdom University of Lille, Inserm U1172, CHU Lille, FHU Precise, Lille, France, France Sanofi, Cambridge, United States, MA Sanofi, Bridgewater, United States, MA Translational Neuroradiology Section, National Institutes of Health, Bethesda, United States, MD
